Find information on Apixaban Therapy (Eliquis), a Factor Xa Inhibitor, for healthcare professionals. Learn about clinical documentation, medical coding, and Apixaban dosage for accurate patient care. This resource covers essential aspects of Eliquis therapy, including administration, monitoring, and potential interactions, crucial for precise medical coding and optimal clinical documentation.
Also known as
Other long term (current) drug therapy
Codes for ongoing use of medications, including apixaban.
Adverse effect of apixaban
Used for complications or side effects due to apixaban.
Personal history of venous embolism
Indicates a history of venous thromboembolism (VTE), for which apixaban may be prescribed.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is apixaban used for prophylaxis?
When to use each related code
| Description |
|---|
| Treatment with apixaban, an oral anticoagulant. |
| Treatment with rivaroxaban, an oral anticoagulant. |
| Treatment with warfarin, an oral anticoagulant. |
Missing dosage strength and frequency for Apixaban (Eliquis) can lead to incorrect billing and patient safety concerns.
Lack of clear documentation for the medical necessity of Apixaban (Factor Xa Inhibitor) therapy can trigger denials.
Miscoding Apixaban (Eliquis) with other anticoagulants due to similar indications requires careful CDI review for accurate coding.
Q: What are the key considerations for managing apixaban therapy in patients with renal impairment?
A: Managing apixaban (Eliquis), a factor Xa inhibitor, in patients with renal impairment requires careful dose adjustments based on creatinine clearance. For patients with a creatinine clearance of 15-29 mL/min, a reduced dose of 2.5 mg twice daily is recommended. For those with a creatinine clearance less than 15 mL/min or on dialysis, apixaban is generally avoided due to limited data and increased bleeding risk. Close monitoring for signs of bleeding and regular assessment of renal function are crucial for optimal apixaban therapy management in these patients. Explore how our clinical decision support tools can help streamline renal dose adjustments for apixaban and other anticoagulants.
Q: How do I reverse apixaban (Eliquis) in the event of a major bleed or urgent surgery?
A: Reversing the anticoagulant effects of apixaban in emergency situations requires prompt action. Andexanet alfa (Andexxa) is a specific reversal agent approved for apixaban-induced bleeding. While four-factor prothrombin complex concentrate (PCC) can be considered if andexanet alfa is unavailable, its efficacy is less established. For life-threatening bleeds, immediate cessation of apixaban and supportive measures are paramount. Consider implementing a standardized protocol for anticoagulant reversal in your practice to ensure rapid and appropriate management of such events. Learn more about the latest guidelines for managing anticoagulation-related bleeding complications.
Patient presents for management of Apixaban therapy, also known as Eliquis therapy, for the prevention or treatment of thromboembolic events. The patient's indication for Apixaban, a Factor Xa inhibitor, was discussed, including a review of potential benefits and risks such as bleeding complications, drug interactions, and the need for consistent medication adherence. Current medication list was reviewed and reconciled. Patient demonstrated understanding of the importance of regular laboratory monitoring, if applicable, as well as when to seek immediate medical attention for signs or symptoms of bleeding or thromboembolism. Patient education regarding dietary considerations while on Apixaban therapy, including limitations on certain foods and supplements, was provided. The prescribed dosage, frequency, and route of administration of Apixaban were thoroughly explained. The patient's renal function and potential drug interactions were assessed as part of medication management. Follow-up appointment was scheduled to monitor treatment efficacy and address any potential adverse effects associated with Apixaban or Eliquis use. The discussion included alternative anticoagulation options and the rationale for selecting Apixaban. This documentation supports medical billing and coding for Apixaban therapy management.